Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  10x Genomics, Inc.    TXG

10X GENOMICS, INC.

(TXG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/24/2020 03/25/2020 03/26/2020 03/27/2020 03/30/2020 Date
57.11(c) 59.99(c) 61.04(c) 59.99(c) 62.8(c) Last
694 187 535 119 307 447 148 529 418 759 Volume
+10.74% +5.04% +1.75% -1.72% +4.68% Change
More quotes
Financials (USD)
Sales 2020 355 M
EBIT 2020 -40,2 M
Net income 2020 -42,4 M
Finance 2020 218 M
Yield 2020 -
Sales 2021 468 M
EBIT 2021 -4,69 M
Net income 2021 -5,68 M
Finance 2021 194 M
Yield 2021 -
P/E ratio 2020 -138x
P/E ratio 2021 -351x
EV / Sales2020 16,5x
EV / Sales2021 12,5x
Capitalization 6 063 M
More Financials
Company
10x Genomics, Inc. is a life science technology company. The Company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The Company’s product consists of chromium single cell... 
More about the company
Surperformance© ratings of 10x Genomics, Inc.
Trading Rating : Investor Rating : -
More Ratings
Latest news on 10X GENOMICS, INC.
03/2610X GENOMICS, INC. : Change in Directors or Principal Officers, Amendments to Ar..
AQ
02/2710X GENOMICS : Management's Discussion and Analysis of Financial Condition and R..
AQ
02/2510x Genomics to Present at the 40th Annual Cowen Health Care Conference
GL
02/2410x Genomics Debuts Range of New Products at AGBT
GL
02/1810X GENOMICS : 4Q Earnings Snapshot
AQ
02/1810X GENOMICS, INC. : Results of Operations and Financial Condition, Financial St..
AQ
02/1810x Genomics Reports Fourth Quarter and Full Year 2019 Financial Results and ..
GL
02/1410X GENOMICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
02/0410x Genomics to Report Fourth Quarter and Full Year 2019 Financial Results on..
GL
01/0710x Genomics to Present at the 38th Annual J.P. Morgan Healthcare Conference
GL
201910X GENOMICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
201910X GENOMICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
201910X GENOMICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
201910x Genomics Begins Shipments of Visium Spatial Gene Expression Solution
GL
201910X GENOMICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
More news
News in other languages on 10X GENOMICS, INC.

- No features available -

More news
Chart 10X GENOMICS, INC.
Duration : Period :
10x Genomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 10X GENOMICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 94,67  $
Last Close Price 62,80  $
Spread / Highest target 79,9%
Spread / Average Target 50,7%
Spread / Lowest Target 19,4%
EPS Revisions
Managers
NameTitle
Serge Saxonov Chief Executive Officer & Director
Benjamin J. Hindson President, Chief Scientific Officer & Director
John R. Stuelpnagel Chairman
Paul W. Wyatt Vice President-Operations
Justin J. McAnear Chief Financial & Accounting Officer
Sector and Competitors
1st jan.Capitalization (M$)
10X GENOMICS, INC.-17.64%6 063
BIOMÉRIEUX26.28%13 056
DIASORIN S.P.A.0.95%7 025
AUTOBIO DIAGNOSTICS CO., LTD.19.07%6 961
GUANGZHOU WONDFO BIOTECH CO.,LTD1.09%3 832
NATERA, INC.-14.54%2 253